Latest developments in the imaging of fibrotic liver disease

Acta Radiologica

Volumn 55, Issue 7, 2014, Pages 802-813

  Sangwaiya, Minal J ^a,b   Sherman, David I N ^a   Lomas, David J ^c   Shorvon, Philip J ^a  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Abdomen GI; Fibrosis; Liver

Indexed keywords

LIVER; PATIENT MONITORING;

ABDOMEN/GI; CHRONIC LIVER DISEASE; FIBROSIS; LATEST DEVELOPMENT; LIVER CIRRHOSIS; LIVER DISEASE; WORLD HEALTH ORGANIZATION;

IMAGING TECHNIQUES;

BIOLOGICAL MARKER;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; ECHOGRAPHY; ELASTOGRAPH; ELASTOGRAPHY; FUTUROLOGY; GRAY SCALE ECHOGRAPHY; HUMAN; LIVER BIOPSY; LIVER EXAMINATION; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE ELASTOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; ABDOMEN/GI; EUROPE; FIBROSIS; FORECASTING; LIVER; LIVER CIRRHOSIS; METABOLISM; METHODOLOGY; MOLECULAR IMAGING;

ABDOMEN/GI; FIBROSIS; LIVER;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; EUROPE; FORECASTING; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR IMAGING;

EID: 84907881794     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185113510159     Document Type: Review

References (86)

1. The burden of liver disease in Europe: European Association for the Study of the Liver, February 2013. See http://www.easl.eu/assets/application/files/54ae845caec619f-file.pdf
2. Office for National Statistics. Deaths: selected causes (International Classification) and sex, 1971 onwards, (England and Wales). Health Stat Q 2003;20:58-59.
3. Burroughs A, Mcnamar D. Liver disease in Europe. Aliment Pharmacol Ther 2003;18:54-59.
4. World Health Organization (European Region) Statistics. See http://www.euro.who.int/en/data-andevidence/databases.
5. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocinol Metab 2005;288:E462-E468.
6. Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007;102:399-408.
7. NHS Information Centre. See www.ic.nhs.uk/statisticsand- data-collections.
8. Adams LA, Sanderson S, Lindor KD, et al. The histological course of non-alcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138.
9. Farrell GC, Larter CZ. Non alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-S112.
10. James O, Day C. Non-alcoholic steato-hepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
11. Povero D, Busletta C, Novo E, et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010;25:1075-1091.
12. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-782.
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
14. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
15. Patel K, Nelson DR, Afdahl N, et al. Prospective evaluation of a serum (FibroSpect II) panel to predict fibrosis in chronic HCV Patients. Gastroenterology 2004;126 (Suppl. 2):A-A708.
16. Fouad SA, Esmat S, Omran D, et al. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol 2012;18:2988-2994.
17. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-1713.
18. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrinogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-481.
19. Callewaert N, van Vlierberghe H, van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer based total serum protein glycomics. Nat Med 2004;10:429-434.
20. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
21. Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Path 2006;125:710-721.
22. Chandarana H, Taouli B. Diffusion and perfusion imaging of the liver. Eur J Radiol 2010;76:348-358.
23. Gheonea DI, Səftoiu A, Ciurea T, et al. Real-time sonoelastography in the diagnosis of diffuse liver diseases. World J Gastroenterol 2010;16:1720-1726.
24. Lewin M, Arrivé L, Lacombe C, et al. Diffusion-weighted MR imaging of liver pathology: principles and clinical applications. J Radiol 2010;91:11-26.
25. Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. Radiographics 2009;29:1591-1614.
26. Qayyum A, Chen DM, Breiman RS, et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clin Imaging 2009;33:110-115.
27. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986;292:13-15.
28. Schacherer D, Schuh C, Strauch U, et al. Improvement in the routine diagnostic assessment of the liver by highresolution sonography: an analysis of 999 cases. Scand J Gastroenterol 2007;42:366-373.
29. Nishiura T, Watanabe H, Ito M, et al. Ultrasound evaluation of the fibrosis stage in chronic liver disease by simultaneous use of low and high frequency probes. Br J Radiol 2005;78:189-197.
30. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31.
31. Simonovský V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. Br J Radiol 1999;72:29-34.
32. Choong CC, Venkatesh SK, Siew EP. Accuracy of routine clinical ultrasound for staging of liver fibrosis. J Clin Imaging Sci 2012;2:58.
33. Barakat M. Non-pulsatile hepatic and portal vein waveforms in patients with liver cirrhosis: concordant and discordant relationships. Br J Radiol 2004;77:547-550.
34. Hatkanir A, Cihan BS, Celenk C, et al. Value of Doppler sonography in assessing the progression of chronic viral hepatitis and in the diagnosis and grading of cirrhosis. J Ultrasound Med 2005;24:311-321.
35. Schneider AR, Teuber G, Kriener S, et al. Noninvasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection. Liver Int 2005;25:1150-1155.
36. Lim AK, Patel N, Eckersley RJ, et al. Can Doppler sonography grade the severity of hepatits C-related liver disease? Am J Roentgenol 2005;184:1848-1853.
37. Liu GJ, Wang W, Xie XY, et al. Real-time contrastenhanced ultrasound imaging of focal liver lesions in fatty liver. Clin Imaging 2010;34:211-221.
38. Piscaglia F, Lencioni R, Sagrini E, et al. Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol 2010;36:531-550.
39. Bartolotta TV, Taibbi A, Midiri M, et al. Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent. Radiol Med 2010;115:714-731.
40. Bang N, Nielsen MB, Rasmussen AN, et al. Hepatic vein transit time of an ultrasound contrast agent: simplified procedure using pulse inversion imaging. Br J Radiol 2001;74:752-755.
41. Searle J, Mendelson R, Zelesco M, et al. Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent: A pilot study. J Med Imaging Radiat Oncol 2008;52:130-133.
42. Abbattista T, Ridolfi F, Ciabattoni E, et al. Diagnosis of liver cirrhosis by transit-time analysis at contrastenhanced ultrasonography. Radiol Med 2008;113:860-874.
43. Blomley MJK, Lim AKP, Harvey CJ, et al. Liver microbubble transit time compared with histology and Child- Pugh score in diffuse liver disease: a cross sectional study. GUT 2003;52:1188-1193.
44. Koizumi Y, Masashi H, Kisaka Y, et al. Liver fibrosis in patients with chronic hepatitis C: non-invasive diagnosis by means of real-time tissue elastography: establishment of the method of measurement. Radiology 2011;258:610-617.
45. See http://www.engineeringtoolbox.com/speed-soundd-82.html.
46. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-974.
47. Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis 2009;18:303-310.
48. Sporea I, Sirli RL, Deleanu A, et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall Med 2010;32:S46-S52.
49. Vispo E, Barreiro P, Del Valle J, et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther 2009;14:187-193.
50. Cohen EB, Afdhal NH. Ultrasound-based hepatic elastography: origins, limitations, and applications. J Clin Gastroenterol 2010;44:637-645.
51. Berzigotti A, De Gottardi A, Vukotic R, et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 2013;8:e58742.
52. Boursier J, de Ledinghen V, Sturm N, et al. Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. J Gastroenterol 2013 May 17. Epub ahead of print.
53. Poggio PD, Colombo S. Is transient elastography a useful tool for screening liver disease? World J Gastroenterol 2009;15:1409-1414.
54. Boulanger Y, Amara M, Lepanto L, et al. Diffusionweighted MR imaging of the liver of hepatitis C patients. NMR Biomed 2003;16:132-136.
55. Moschcowitz E. The pathogenesis of splenomegaly in hypertension of the portal circulation; congestive splenomegaly. Medicine 1948;27:187-221.
56. Schwenzer NF, Springer F, Schraml C, et al. Non-invasic assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-445.
57. Jang HJ, Yu H, Kim TK. Imaging of focal liver lesions. Semin Roentgenol 2009;44:266-282.
58. Ronot M, Asselah T, Paradis V, et al. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology 2010;256:135-142.
59. Kalra MK, Maher MM, Blake MA, et al. Detection and characterization of lesions on low-radiation-dose abdominal CT images postprocessed with noise reduction filters. Radiology 2004;232:791-797.
60. Singh S, Kalra MK, Hsieh J, et al. Abdominal CT: comparison of adaptive statistical iterative and filtered back projection reconstruction techniques. Radiology 2010;257:373-383.
61. Prakash P, Kalra MK, Kambadakone AK, et al. Reducing abdominal CT radiation dose with adaptive statistical iterative reconstruction technique. Invest Radiol 2010;45:202-210.
62. Ohtomo K, Baron RL, Dodd GD 3rd, et al. Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 1993;189:871-874.
63. Aguirre DA, Behling CA, Alpert E, et al. Liver fibrosis: noninvasive diagnosis with double contrast materialenhanced MR imaging. Radiology 2006;239:425-437.
64. Lucidarme O, Baleston F, Cadi M, et al. Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol 2003;13:467-474.
65. Nojiri S, Kasukabe A, Fujiwara K, et al. Noninvasive evaluation of hepatic fibrosis in HCV-infected patients using EOB-MR imaging. J Gastroenterol Hepatol 2013;28:1032-1039.
66. Martí-Bonmatí L, Lonjedo E, Poyatos C, et al. MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers. Invest Radiol 1998;33:717-722.
67. Hayashi T, Miyati T, Takahashi J, et al. Diffusion analysis with triexponential function in liver cirrhosis. J Magn Reson Imaging 2013;38:148-153.
68. Kanematsu M, Goshima S, Watanabe H, et al. Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. Magn Reson Med Sci 2012;11:151-161.
69. Wang QB, Zhu H, Liu HL, et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology 2012;56:239-247.
70. Noren B, Dahlqvist O, Lundberg P, et al. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. Eur J Radiol 2008;66:313-320.
71. Dezortova M, Taimr P, Skoch A, et al. Etiology and functional status of liver cirrhosis by 31P MR spectroscopy. World J Gastroenterol 2005;11:6926-6931.
72. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010;51:828-835.
73. Rouvière O, Yin M, Dresner MA, et al. MR elastography of the liver: preliminary results. Radiology 2006;240:440-448.
74. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5:1207-1213.
75. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008;135:32-40.
76. Reeder SB, Robson PM, Yu H, et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009;29:1332-1339.
77. Motosugi U, Ichikawa T, Sano K, et al. Magnetic resonance elastography of the liver: preliminary results and estimation of inter-rater reliability. Jpn J Radiol 2010;28:623-627.
78. Hines CD, Lindstrom MJ, Varma AK, et al. Effects of postprandial state and mesenteric blood flow on the repeatability of MR elastography in asymptomatic subjects. J Magn Reson Imaging 2011;33:239-244.
79. Asbach P, Klatt D, Schlosser B, et al. Viscoelasticitybased staging of hepatic fibrosis with multifrequency MR elastography. Radiology 2010;257:80-86.
80. Cosgrove D, Piscaglia F, Bamber J, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography Part 2: Clinical Applications. Ultraschall Med 2013;34:238-253.
81. Sheng-Nan Lu, Chao-Hung, Hung, et al. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int 2010;4:700-706.
82. Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:481-486.
83. Westin J, Lagging LM, Wejstal R, et al. Interobserver study of liver histopathology using Ishak score in patients with chronic hepatitis C virus infection. Liver 1999;19:169-170.
84. Gronaek K, Christensen PB, Hamilton-Dutoit S, et al. Interobserver variation in interpretation of serial liver biopsies from patient with chronic hepatitis C. J Viral Hepat 2002;9:443-449.
85. Standish RA, Cholangitas E, Dhillon A, et al. An appraisal of the histopathological assessment of liver fibrosis. GUT 2006;55:569-578.
86. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. LIDO Study Group. Gastroenterology 2005;128:1898-1906.